Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid 1Leukemia 1

Interventions

venetoclax 3Imatinib Mesylate 3ponatinib 2nilotinib 2Dasatinib 2Azacitidine 2zileuton 1thymoglobulin 1pulrodemstat besilate 1posaconazole 1emvododstat 1Transplantation 1Standard of Care 1Mycophenolic Acid 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Lenalidomide 1IMC-EB10 1Homoharringtonine 1HhAntag691 1Hematopoietic Stem Cell Transplantation 1Decitabine 1Cytarabine 1Cyclosporine 1CC 401 1BID protein, human 1Antilymphocyte Serum 1AVE9633 13-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid × CC 401 × Clear all
NCT00126893 2007-05-15

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Celgene

Phase 1 Terminated
36 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡